European Commission Grants Conditional Marketing Authorisation for Roche's Lunsumio Subcutaneous for Relapsed or Refractory Follicular Lymphoma
Wednesday, November 19, 2025
The European Commission (EC) has today granted conditional marketing authorisation to Roche’s Lunsumio® (mosunetuzumab) in its subcutaneous (SC) formulation for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have undergone at least two prior systemic therapies. This pivotal regulatory development places Roche at the forefront of advancing bispecific antibody therapies in Europe, providing new hope for patients with B-cell non-Hodgkin lymphoma, a disease that becomes increasingly challenging to treat with each relapse.
Lunsumio SC is highly significant for both clinical and operational reasons. Unlike its intravenous (IV) counterpart, the subcutaneous formulation offers a much-reduced administration time of approximately one minute. This represents a major step forward in terms of efficiency, patient throughput, and hospital resource utilisation. The EC's decision is grounded in results from the phase I/II GO29781 study, which established pharmacokinetic non-inferiority between the SC and IV formulations, while confirming a comparable safety profile and strong efficacy outcomes. The therapy is particularly relevant for third-line or later patients, where response durability is crucial—prior studies have shown that 57% of complete responders maintained remission at five years with the IV formulation.
Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development, commented, "Developing new formulations of our medicines is part of our commitment to offering greater flexibility and a better treatment experience for patients." By enabling rapid, fixed-duration dosing, Lunsumio SC allows treatment to be tailored more precisely to patient and system needs whilst also supporting improved adherence and reduced burden on oncology departments. These attributes are increasingly sought after in the evolving landscape of cancer care, where efficient care delivery and patient-centric approaches are in high demand.
The EC approval is based on robust evidence. The pivotal GO29781 trial spanned multiple centres across Europe, systematically evaluating dosage and treatment protocols across both IV and subcutaneous cohorts. Key clinical endpoints included complete response (CR) rates, objective response rate (ORR), progression-free survival (PFS), safety, and tolerability, with results substantiating the drug’s benefit-risk profile for this hard-to-treat lymphoma. Notably, the SC formulation’s administration ease is poised to have positive downstream effects on quality of life for patients and could facilitate more widespread and equitable access throughout healthcare systems facing capacity constraints.
For the European B2B pharma community, this regulatory development is expected to influence portfolio strategies, commercial operations, and supply chain models for both Roche and competitors. With the EC's conditional marketing authorisation, Lunsumio SC also lays the foundation for further expansion in therapeutic indications and possible combination therapies—the molecule is already under investigation in the MorningLyte phase III study for use with lenalidomide in previously untreated FL, along with studies in diffuse large B-cell lymphoma and other blood cancers. Roche’s commitment to combination regimens based on its CD20xCD3 bispecific antibody portfolio remains a key differentiator, and this latest milestone consolidates its position as an industry leader in haematology innovation.
The EC authorisation is accompanied by ongoing regulatory filings and submissions in global markets, including the US Food and Drug Administration (FDA). Meanwhile, long-term results from both SC and IV arms will be highlighted at leading international scientific meetings, offering the global scientific community continued access to the latest clinical and translational data.
This approval marks a new era in patient care and treatment flexibility for haematological malignancies in Europe, with rippling effects expected throughout the competitive and regulatory environment. Roche’s industrial capabilities, commitment to scientific research, and strategic investment in next-generation antibody therapies position the company—and its European partners—at the technological and business vanguard as they adapt to increasingly complex healthcare requirements.
